As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
Zero Shot, a new venture capital fund with deep ties to OpenAI, is aiming to raise $100 million for its first fund. It has already written some checks.
Contrary to popular belief, cutting out procrastination isn’t a matter of willpower or even self-discipline. You don’t need to punish yourself. You need a system.
In 2026, buyers want more than a SOC 2 badge. They expect a clear security evidence pack that shows how your company handles data, uptime, hosting and incident response before they approve a pilot.
Contrary to popular belief, cutting out procrastination isn’t a matter of willpower or even self-discipline. You don’t need to punish yourself. You need a system.